- Home
- BEEP vs MRSN Comparison
BEEP vs MRSN Comparison
Compare BEEP & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEEP | MRSN |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 138.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BEEP | MRSN |
|---|---|---|
| Price | $2.84 | $28.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.75 | ★ $30.38 |
| AVG Volume (30 Days) | 55.7K | ★ 237.7K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,470,000.00 | $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $5.21 |
| 52 Week High | $4.86 | $70.73 |
Technical Indicators
Market Signals| Indicator | BEEP | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 84.36 |
| Support Level | $2.50 | $27.31 |
| Resistance Level | $3.20 | $28.36 |
| Average True Range (ATR) | 0.21 | 0.53 |
| MACD | -0.02 | -0.41 |
| Stochastic Oscillator | 48.57 | 66.89 |
Price Performance
Historical ComparisonAbout BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provide access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.